Copyright © 2012 Xiaolong Qi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. L. Veenman and M. Gavish, “The peripheral-type benzodiazepine receptor and the cardiovascular system. Implications for drug development,” Pharmacology & Therapeutics, vol. 110, no. 3, pp. 503–524, 2006. View at Publisher · View at Google Scholar · View at Scopus
2. R. Rupprecht, V. Papadopoulos, G. Rammes et al., “Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders,” Nature Reviews Drug Discovery, vol. 9, no. 12, pp. 971–988, 2010. View at Publisher · View at Google Scholar · View at Scopus
3. V. Papadopoulos, M. Baraldi, T. R. Guilarte et al., “Translocator protein (18 kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function,” Trends in Pharmacological Sciences, vol. 27, no. 8, pp. 402–409, 2006. View at Publisher · View at Google Scholar · View at Scopus
4. S. Surinkaew, S. Chattipakorn, and N. Chattipakorn, “Roles of mitochondrial benzodiazepine receptor in the heart,” Canadian Journal of Cardiology, vol. 27, no. 2, pp. 262.e3–262.e13, 2011. View at Publisher · View at Google Scholar · View at Scopus
5. J. Fan, P. Lindemann, M. G. Feuilloley, and V. Papadopoulos, “Structural and functional evolution of the translocator protein (18 kDa),” Current Molecular Medicine, vol. 12, no. 4, pp. 369–386, 2012. View at Publisher · View at Google Scholar
6. A. Batarseh, J. Li, and V. Papadopoulos, “Protein kinase Cε regulation of translocator protein (18 kDa) Tspo gene expression is mediated through a MAPK pathway targeting STAT3 and c-Jun transcription factors,” Biochemistry, vol. 49, no. 23, pp. 4766–4778, 2010. View at Publisher · View at Google Scholar · View at Scopus
7. J. Li, J. Xiao, D. Liang et al., “Inhibition of mitochondrial translocator protein prevents atrial fibrillation,” European Journal of Pharmacology, vol. 632, no. 1–3, pp. 60–64, 2010. View at Publisher · View at Google Scholar · View at Scopus
8. F. G. Akar, M. A. Aon, G. F. Tomaselli, and B. O'Rourke, “The mitochondrial origin of postischemic arrhythmias,” The Journal of Clinical Investigation, vol. 115, no. 12, pp. 3527–3535, 2005. View at Publisher · View at Google Scholar · View at Scopus
9. D. A. Brown and B. O'Rourke, “Cardiac mitochondria and arrhythmias,” Cardiovascular Research, vol. 88, no. 2, pp. 241–249, 2010. View at Publisher · View at Google Scholar · View at Scopus
10. M. A. Aon, S. Cortassa, F. G. Akar, and B. O'Rourke, “Mitochondrial criticality: a new concept at the turning point of life or death,” Biochimica et Biophysica Acta, vol. 1762, no. 2, pp. 232–240, 2006. View at Publisher · View at Google Scholar · View at Scopus
11. A. Jaiswal, S. Kumar, R. Enjamoori, S. Seth, A. K. Dinda, and S. K. Maulik, “Peripheral benzodiazepine receptor ligand Ro5-4864 inhibits isoprenaline-induced cardiac hypertrophy in rats,” European Journal of Pharmacology, vol. 644, no. 1–3, pp. 146–153, 2010. View at Publisher · View at Google Scholar · View at Scopus
12. O. Gaemperli, J. Shalhoub, D. R. Owen, F. Lamare, S. Johansson, et al., “Imaging intraplaque inflammation in carotid atherosclerosis with ¹¹C-PK11195 positron emission tomography/computed tomography,” Europen Heart Journal, vol. 33, no. 15, pp. 1902–1910, 2012. View at Publisher · View at Google Scholar
13. I. Kindermann, C. Barth, F. Mahfoud, C. Ukena, M. Lenski, et al., “Update on myocarditis,” Journal of the American College of Cardiology, vol. 59, no. 9, pp. 779–792, 2012. View at Publisher · View at Google Scholar
14. S. Sagar, P. P. Liu, and L. T. Cooper Jr., “Myocarditis,” The Lancet, vol. 379, no. 9817, pp. 738–747, 2012. View at Publisher · View at Google Scholar
15. F. Lamare, R. Hinz, O. Gaemperli et al., “Detection and quantification of large-vessel inflammation with ¹¹C-(R)-PK11195 PET/CT,” Journal of Nuclear Medicine, vol. 52, no. 1, pp. 33–39, 2011. View at Publisher · View at Google Scholar · View at Scopus
16. J. Xu, J. Zhao, G. Evan, C. Xiao, Y. Cheng, et al., “Circulating microRNAs: novel biomarkers for cardiovascular diseases,” Journal of Molecular Medicine, vol. 90, no. 8, pp. 865–875, 2012. View at Publisher · View at Google Scholar
17. C. J. O'Donnell and E. G. Nabel, “Genomics of cardiovascular disease,” The New England Journal of Medicine, vol. 365, pp. 2098–2109, 2011. View at Publisher · View at Google Scholar
18. J. L. Goldstein and M. S. Brown, “The LDL receptor,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 29, no. 4, pp. 431–438, 2009. View at Publisher · View at Google Scholar · View at Scopus
19. C. P. Baines, R. A. Kaiser, T. Sheiko, W. J. Craigen, and J. D. Molkentin, “Voltage-dependent anion channels are dispensable for mitochondrial-dependent cell death,” Nature Cell Biology, vol. 9, no. 5, pp. 550–555, 2007. View at Publisher · View at Google Scholar · View at Scopus
20. J. E. Kokoszka, K. G. Waymire, S. E. Levy et al., “The ADP/ATP translocator is not essential for the mitochondrial permeability transition pore,” Nature, vol. 427, no. 6973, pp. 461–465, 2004. View at Publisher · View at Google Scholar · View at Scopus
21. O. R. Kunduzova, G. Escourrou, F. De La Farge et al., “Involvement of peripheral benzodiazepine receptor in the oxidative stress, death-signaling pathways, and renal injury induced by ischemia-reperfusion,” Journal of the American Society of Nephrology, vol. 15, no. 8, pp. 2152–2160, 2004. View at Publisher · View at Google Scholar · View at Scopus
22. E. G. Jordà, A. Jiménez, E. Verdaguer et al., “Evidence in favour of a role for peripheral-type benzodiazepine receptor ligands in amplification of neuronal apoptosis,” Apoptosis, vol. 10, no. 1, pp. 91–104, 2005. View at Publisher · View at Google Scholar · View at Scopus
23. L. Betti, G. Giannaccini, M. Nigro, S. Dianda, V. Gremigni, and A. Lucacchini, “Studies of peripheral benzodiazepine receptors in mussels: comparison between a polluted and a nonpolluted site,” Ecotoxicology and Environmental Safety, vol. 54, no. 1, pp. 36–42, 2003. View at Publisher · View at Google Scholar · View at Scopus
24. S. Galiègue, P. Casellas, A. Kramar, N. Tinel, and J. Simony-Lafontaine, “Immunohistochemical assessment of the peripheral benzodiazepine receptor in breast cancer and its relationship with survival,” Clinical Cancer Research, vol. 10, no. 6, pp. 2058–2064, 2004. View at Publisher · View at Google Scholar · View at Scopus
25. L. Veenman, E. Levin, G. Weisinger et al., “Peripheral-type benzodiazepine receptor density and in vitro tumorigenicity of glioma cell lines,” Biochemical Pharmacology, vol. 68, no. 4, pp. 689–698, 2004. View at Publisher · View at Google Scholar · View at Scopus
26. N. Leducq, F. Bono, T. Sulpice et al., “Role of peripheral benzodiazepine receptors in mitochondrial, cellular, and cardiac damage induced by oxidative stress and ischemia-reperfusion,” Journal of Pharmacology and Experimental Therapeutics, vol. 306, no. 3, pp. 828–837, 2003. View at Publisher · View at Google Scholar · View at Scopus
27. D. Kletsas, W. Li, Z. Han, and V. Papadopoulos, “Peripheral-type benzodiazepine receptor (PBR) and PBR drug ligands in fibroblast and fibrosarcoma cell proliferation: role of ERK, c-Jun and ligand-activated PBR-independent pathways,” Biochemical Pharmacology, vol. 67, no. 10, pp. 1927–1932, 2004. View at Publisher · View at Google Scholar · View at Scopus
28. M. K. Chen and T. R. Guilarte, “Translocator protein 18kDa (TSPO): molecular sensor of brain injury and repair,” Pharmacology & Therapeutics, vol. 118, no. 1, pp. 1–17, 2008. View at Publisher · View at Google Scholar · View at Scopus
29. K. Saegusa, Y. Furukawa, and Y. Ogiwara, “Pharmacologic basis of responses to midazolam in the isolated, cross-perfused, canine right atrium,” Anesthesia and Analgesia, vol. 66, no. 8, pp. 711–718, 1987. View at Scopus
30. Y. Edoute, J. Giris, S. A. Ben-Haim et al., “Ro 5-4864 and PK 11195, but not diazepam, depress cardiac function in an isolated working rat heart model,” Pharmacology, vol. 46, no. 4, pp. 224–230, 1993. View at Scopus
31. M. Mestre, T. Carriot, C. Belin, et al., “Electrophysiological and pharmacological evidence that peripheral type benzodiazepine receptors are coupled to calcium channels in the heart,” Life Sciences, vol. 36, no. 4, pp. 391–400, 1985. View at Publisher · View at Google Scholar · View at Scopus
32. J. Li, J. Xiao, Y. Liu et al., “Mitochondrial benzodiazepine receptors mediate cardioprotection of estrogen against ischemic ventricular fibrillation,” Pharmacological Research, vol. 60, no. 1, pp. 61–67, 2009. View at Publisher · View at Google Scholar · View at Scopus
33. I. L. Grupp, J. F. French, and M. A. Matlib, “Benzodiazepine Ro 5-4864 increases coronary flow,” European Journal of Pharmacology, vol. 143, no. 1, pp. 143–147, 1987. View at Scopus
34. B. A. Weissman, G. T. Bolger, and P. K. Chiang, “Interactions between nitrogen oxide-containing compounds and peripheral benzodiazepine receptors,” FEBS Letters, vol. 260, no. 2, pp. 169–172, 1990. View at Scopus
35. M. Mestre, T. Carriot, C. Belin, et al., “Electrophysiological and pharmacological characterization of peripheral benzodiazepine receptors in a guinea pig heart preparation,” Life Sciences, vol. 35, no. 9, pp. 953–962, 1984. View at Publisher · View at Google Scholar · View at Scopus
36. M. Holck and W. Osterrieder, “The peripheral, high affinity benzodiazepine binding site is not coupled to the cardiac Ca²⁺ channel,” European Journal of Pharmacology, vol. 118, no. 3, pp. 293–301, 1985. View at Publisher · View at Google Scholar · View at Scopus
37. D. A. Brown, M. A. Aon, F. G. Akar, T. Liu, N. Sorarrain, and B. O'Rourke, “Effects of $4^{\prime }$-chlorodiazepam on cellular excitation-contraction coupling and ischaemia-reperfusion injury in rabbit heart,” Cardiovascular Research, vol. 79, no. 1, pp. 141–149, 2008. View at Publisher · View at Google Scholar · View at Scopus
38. R. S. Leeuwin, A. Zeegers, J. van Hamme, and H. van Wilgenburg, “Modification of cardiac actions of RO 05-4864 by PK 11195 and flumazenil in the perfused rat heart,” Life Sciences, vol. 61, no. 17, pp. 1631–1642, 1997. View at Publisher · View at Google Scholar · View at Scopus
39. P. Charbonneau, A. Syrota, C. Crouzel, et al., “Peripheral-type benzodiazepine receptors in the living heart characterized by positron emission tomography,” Circulation, vol. 73, no. 3, pp. 476–483, 1986. View at Scopus
40. M. L. James, S. Selleri, and M. Kassiou, “Development of ligands for the peripheral benzodiazepine receptor,” Current Medicinal Chemistry, vol. 13, no. 17, pp. 1991–2001, 2006. View at Publisher · View at Google Scholar · View at Scopus
41. R. B. Banati, “Visualising microglial activation in vivo,” Glia, vol. 40, no. 2, pp. 206–217, 2002. View at Publisher · View at Google Scholar · View at Scopus
42. S. Schaller, S. Paradis, G. A. Ngoh et al., “TRO40303, a new cardioprotective compound, inhibits mitochondrial permeability transition,” Journal of Pharmacology and Experimental Therapeutics, vol. 333, no. 3, pp. 696–706, 2010. View at Publisher · View at Google Scholar · View at Scopus
43. M. A. Aon, S. Cortassa, F. G. Akar, D. A. Brown, L. Zhou, and B. O'Rourke, “From mitochondrial dynamics to arrhythmias,” The International Journal of Biochemistry & Cell Biology, vol. 41, no. 10, pp. 1940–1948, 2009. View at Publisher · View at Google Scholar · View at Scopus
44. C. Schmidt, J. Kisselbach, P. A. Schweizer, H. A. Katus, and D. Thomas, “The pathology and treatment of cardiac arrhythmias: focus on atrial fibrillation,” Vascular Health and Risk Management, vol. 7, pp. 193–202, 2011. View at Scopus
45. L. S. Wann, A. B. Curtis, C. T. January et al., “2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American college of cardiology foundation/American heart association task force on practice guidelines,” Circulation, vol. 123, no. 1, pp. 104–123, 2011. View at Publisher · View at Google Scholar · View at Scopus
46. J. Li, J. Xu, J. Xiao et al., “Preservation of TSPO by chronic intermittent hypobaric hypoxia confers antiarrhythmic activity,” Journal of Cellular and Molecular Medicine, vol. 15, no. 1, pp. 134–140, 2011. View at Publisher · View at Google Scholar · View at Scopus
47. N. R. Brady, A. Hamacher-Brady, H. V. Westerhoff, and R. A. Gottlieb, “A wave of reactive oxygen species (ROS)-induced ROS release in a sea of excitable mitochondria,” Antioxidants and Redox Signaling, vol. 8, no. 9-10, pp. 1651–1665, 2006. View at Publisher · View at Google Scholar · View at Scopus
48. D. B. Zorov, M. Juhaszova, and S. J. Sollott, “Mitochondrial ROS-induced ROS release: an update and review,” Biochimica et Biophysica Acta, vol. 1757, no. 5-6, pp. 509–517, 2006. View at Publisher · View at Google Scholar · View at Scopus
49. J. Cho, K. Won, D. Wu et al., “Potent mitochondria-targeted peptides reduce myocardial infarction in rats,” Coronary Artery Disease, vol. 18, no. 3, pp. 215–220, 2007. View at Publisher · View at Google Scholar · View at Scopus
50. M. A. Aon, S. Cortassa, C. Maack, and B. O'Rourke, “Sequential opening of mitochondrial ion channels as a function of glutathione redox thiol status,” The Journal of Biological Chemistry, vol. 282, no. 30, pp. 21889–21900, 2007. View at Publisher · View at Google Scholar · View at Scopus
51. M. A. Aon, S. Cortassa, E. Marbán, and B. O'Rourke, “Synchronized whole cell oscillations in mitochondrial metabolism triggered by a local release of reactive oxygen species in cardiac myocytes,” The Journal of Biological Chemistry, vol. 278, no. 45, pp. 44735–44744, 2003. View at Publisher · View at Google Scholar · View at Scopus
52. M. A. Aon, S. Cortassa, and B. O'Rourke, “Mitochondrial oscillations in physiology and pathophysiology,” Advances in Experimental Medicine and Biology, vol. 641, pp. 98–117, 2008. View at Publisher · View at Google Scholar · View at Scopus
53. D. A. Brown, M. A. Aon, C. R. Frasier et al., “Cardiac arrhythmias induced by glutathione oxidation can be inhibited by preventing mitochondrial depolarization,” Journal of Molecular and Cellular Cardiology, vol. 48, no. 4, pp. 673–679, 2010. View at Publisher · View at Google Scholar · View at Scopus
54. C. Piot, P. Croisille, P. Staat et al., “Effect of cyclosporine on reperfusion injury in acute myocardial infarction,” The New England Journal of Medicine, vol. 359, no. 5, pp. 473–481, 2008. View at Publisher · View at Google Scholar · View at Scopus
55. G. E. Billman, “The cardiac sarcolemmal ATP-sensitive potassium channel as a novel target for anti-arrhythmic therapy,” Pharmacology & Therapeutics, vol. 120, no. 1, pp. 54–70, 2008. View at Publisher · View at Google Scholar · View at Scopus
56. E. Dongó, I. Hornyák, Z. Benko, and L. Kiss, “The cardioprotective potential of hydrogen sulfide in myocardial ischemia/reperfusion injury,” Acta Physiologica Hungarica, vol. 98, no. 4, pp. 369–381, 2011. View at Publisher · View at Google Scholar
57. D. A. Liem, H. M. Honda, J. Zhang, D. Woo, and P. Ping, “Past and present course of cardioprotection against ischemia-reperfusion injury,” Journal of Applied Physiology, vol. 103, no. 6, pp. 2129–2136, 2007. View at Publisher · View at Google Scholar · View at Scopus
58. P. Ferdinandy, R. Schulz, and G. F. Baxter, “Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning,” Pharmacological Reviews, vol. 59, no. 4, pp. 418–458, 2007. View at Publisher · View at Google Scholar · View at Scopus
59. A. P. Halestrap, “What is the mitochondrial permeability transition pore?” Journal of Molecular and Cellular Cardiology, vol. 46, no. 6, pp. 821–831, 2009. View at Publisher · View at Google Scholar · View at Scopus
60. F. Ricchelli, J. Šileikyte, and P. Bernardi, “Shedding light on the mitochondrial permeability transition,” Biochimica et Biophysica Acta, vol. 1807, no. 5, pp. 482–490, 2011. View at Publisher · View at Google Scholar · View at Scopus
61. L. Argaud, O. Gateau-Roesch, D. Muntean et al., “Specific inhibition of the mitochondrial permeability transition prevents lethal reperfusion injury,” Journal of Molecular and Cellular Cardiology, vol. 38, no. 2, pp. 367–374, 2005. View at Publisher · View at Google Scholar · View at Scopus
62. N. Oka, L. Wang, W. Mi, W. Zhu, O. Honjo, and C. A. Caldarone, “Cyclosporine A prevents apoptosis-related mitochondrial dysfunction after neonatal cardioplegic arrest,” The Journal of Thoracic and Cardiovascular Surgery, vol. 135, no. 1, pp. 123.e2–130.e2, 2008. View at Publisher · View at Google Scholar · View at Scopus
63. J. Šileikyte, V. Petronilli, A. Zulian et al., “Regulation of the inner membrane mitochondrial permeability transition by the outer membrane translocator protein (peripheral benzodiazepine receptor),” The Journal of Biological Chemistry, vol. 286, no. 2, pp. 1046–1053, 2011. View at Publisher · View at Google Scholar · View at Scopus
64. J. Xiao, D. Liang, H. Zhang, Y. Liu, F. Li, and Y. H. Chen, “$4^{\prime }$-chlorodiazepam, a translocator protein (18 kDa) antagonist, improves cardiac functional recovery during postischemia reperfusion in rats,” Experimental Biology and Medicine, vol. 235, no. 4, pp. 478–486, 2010. View at Publisher · View at Google Scholar · View at Scopus
65. F. N. Obame, R. Zini, R. Souktani, A. Berdeaux, and D. Morin, “Peripheral benzodiazepine receptor-induced myocardial protection is mediated by inhibition of mitochondrial membrane permeabilization,” Journal of Pharmacology and Experimental Therapeutics, vol. 323, no. 1, pp. 336–345, 2007. View at Publisher · View at Google Scholar · View at Scopus
66. S. K. Maulik and S. Kumar, “Oxidative stress and cardiac hypertrophy: a review,” Toxicology Mechanisms Methods, vol. 22, pp. 359–366, 2012. View at Publisher · View at Google Scholar
67. J. F. X. Ainscough, M. J. Drinkhill, A. Sedo et al., “Angiotensin II type-1 receptor activation in the adult heart causes blood pressure-independent hypertrophy and cardiac dysfunction,” Cardiovascular Research, vol. 81, no. 3, pp. 592–600, 2009. View at Publisher · View at Google Scholar · View at Scopus
68. M. P. Gupta, “Factors controlling cardiac myosin-isoform shift during hypertrophy and heart failure,” Journal of Molecular and Cellular Cardiology, vol. 43, no. 4, pp. 388–403, 2007. View at Publisher · View at Google Scholar · View at Scopus
69. H. Tsutsui, S. Kinugawa, and S. Matsushima, “Mitochondrial oxidative stress and dysfunction in myocardial remodelling,” Cardiovascular Research, vol. 81, no. 3, pp. 449–456, 2009. View at Publisher · View at Google Scholar · View at Scopus
70. D. Badenhorst, D. Veliotes, M. Maseko et al., “β-adrenergic activation initiates chamber dilatation in concentric hypertrophy,” Hypertension, vol. 41, no. 3, pp. 499–504, 2003. View at Publisher · View at Google Scholar · View at Scopus
71. E. A. van Vré, I. van Brussel, J. M. Bosmans, et al., “Dendritic cells in human atherosclerosis: from circulation to atherosclerotic plaques,” Mediators of Inflammation, vol. 2011, Article ID 941396, 13 pages, 2011. View at Publisher · View at Google Scholar
72. E. Thorp, M. Subramanian, and I. Tabas, “The role of macrophages and dendritic cells in the clearance of apoptotic cells in advanced atherosclerosis,” European Journal of Immunology, vol. 41, no. 9, pp. 2515–2518, 2011. View at Publisher · View at Google Scholar
73. Y. Fujimura, P. M. Hwang, H. Trout III et al., “Increased peripheral benzodiazepine receptors in arterial plaque of patients with atherosclerosis: an autoradiographic study with [³H]PK 11195,” Atherosclerosis, vol. 201, no. 1, pp. 108–111, 2008. View at Publisher · View at Google Scholar · View at Scopus
74. J. G. Park and G. T. Oh, “The role of peroxidases in the pathogenesis of atherosclerosis,” BMB Reports, vol. 44, no. 8, pp. 497–505, 2011. View at Publisher · View at Google Scholar
75. J. L. E. Bird, D. Izquierdo-Garcia, J. R. Davies et al., “Evaluation of translocator protein quantification as a tool for characterising macrophage burden in human carotid atherosclerosis,” Atherosclerosis, vol. 210, no. 2, pp. 388–391, 2010. View at Publisher · View at Google Scholar · View at Scopus
76. I. Laitinen, P. Marjamäki, K. Någren et al., “Uptake of inflammatory cell marker [¹¹C]PK11195 into mouse atherosclerotic plaques,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 36, no. 1, pp. 73–80, 2009. View at Publisher · View at Google Scholar · View at Scopus
77. J. Dimitrova-Shumkovska, L. Veenman, T. Ristoski, S. Leschiner, and M. Gavish, “Chronic high fat, high cholesterol supplementation decreases 18 kDa translocator protein binding capacity in association with increased oxidative stress in rat liver and aorta,” Food and Chemical Toxicology, vol. 48, no. 3, pp. 910–921, 2010. View at Publisher · View at Google Scholar · View at Scopus
78. D. Fatkin and members of the CSANZ Cardiac Genetic Diseases Council Writing Group, “Guidelines for the diagnosis and management of familial dilated cardiomyopathy,” Heart, Lung and Circulation, vol. 20, no. 11, pp. 691–693, 2011.
79. M. Movsesian, O. Wever-Pinzon, and F. Vandeput, “PDE3 inhibition in dilated cardiomyopathy,” Current Opinion in Pharmacology, vol. 11, no. 6, pp. 707–713, 2011. View at Publisher · View at Google Scholar
80. A. Fabre and M. N. Sheppard, “Sudden adult death syndrome and other non-ischaemic causes of sudden cardiac death,” Heart, vol. 92, no. 3, pp. 316–320, 2006. View at Publisher · View at Google Scholar · View at Scopus
81. J. A. Onyimba, M. J. Coronado, A. E. Garton, J. B. Kim, A. Bucek, et al., “The innate immune response to coxsackievirus B3 predicts progression to cardiovascular disease and heart failure in male mice,” Biology of Sex Differences, vol. 2, article 2, 2011. View at Publisher · View at Google Scholar
82. S. Frisancho-Kiss, S. E. Davis, J. F. Nyland et al., “Cutting edge: cross-regulation by TLR4 and T cell Ig mucin-3 determines sex differences in inflammatory heart disease,” The Journal of Immunology, vol. 178, no. 11, pp. 6710–6714, 2007. View at Scopus
83. N. Pipitone, A. Versari, and C. Salvarani, “Role of imaging studies in the diagnosis and follow-up of large-vessel vasculitis: an update,” Rheumatology, vol. 47, no. 4, pp. 403–408, 2008. View at Publisher · View at Google Scholar · View at Scopus
84. A. Gulati and A. Bagga, “Large vessel vasculitis,” Pediatric Nephrology, vol. 25, no. 6, pp. 1037–1048, 2010. View at Publisher · View at Google Scholar · View at Scopus
85. L. Caspary and S. Schellong, “Large vessel vasculitis,” Der Internist, vol. 50, no. 8, pp. 958–963, 2009. View at Publisher · View at Google Scholar · View at Scopus
86. K. Sano, “Takayasu disease—pulseless disease,” Brain and Nerve, vol. 60, no. 1, pp. 31–35, 2008. View at Scopus
87. A. Gerhard, J. Schwarz, R. Myers, R. Wise, and R. B. Banati, “Evolution of microglial activation in patients after ischemic stroke: a [¹¹C](R)-PK11195 PET study,” NeuroImage, vol. 24, no. 2, pp. 591–595, 2005. View at Publisher · View at Google Scholar · View at Scopus
88. B. N. van Berckel, M. G. Bossong, R. Boellaard et al., “Microglia activation in recent-onset schizophrenia: a quantitative (R)-[¹¹C]PK11195 positron emission tomography study,” Biological Psychiatry, vol. 64, no. 9, pp. 820–822, 2008. View at Publisher · View at Google Scholar · View at Scopus
89. F. Pugliese, O. Gaemperli, A. R. Kinderlerer et al., “Imaging of vascular inflammation with [¹¹C]-PK11195 and positron emission tomography/computed tomography angiography,” Journal of the American College of Cardiology, vol. 56, no. 8, pp. 653–661, 2010. View at Publisher · View at Google Scholar · View at Scopus
90. Y. Fujimura, P. M. Hwang, H. Trout III et al., “Increased peripheral benzodiazepine receptors in arterial plaque of patients with atherosclerosis: an autoradiographic study with [³H]PK 11195,” Atherosclerosis, vol. 201, no. 1, pp. 108–111, 2008. View at Publisher · View at Google Scholar · View at Scopus